ArticleMaedica2024
Micro-Epigenetic Markers in Viral Genome: SARS-CoV-2 Infection Impact on Host Cell MicroRNA Landscape.
Article in Maedica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMicroRNAs (miRs) are crucial micro-genetic markers that significantly manipulate gene expression in neoplastic/malignant and non-neoplastic diseases, as viral infections. Different expression patterns of miRs seem to partially influence the response rates to specific chemo-targeted therapeutic regimens and prognosis in cancer patients. Concerning their nature, miRs are short non-coding RNAs including 20-25 nucleotides hosted in intra- or intergenic regions. Their most important function is the positive regulation of post-transcriptional gene silencing levels. Based on this activity, they enhance normal cell functions, including proliferation, apoptosis and tissue differentiation. Their deregulation in cancerous cells due to epigenetic and transcriptional imbalances is correlated with an excessive production of target mRNA.
objectiveIn the current paper, our aim was to generally describe the role of MiRs in cancer genome and we mainly focused on specific host target-cell miRs that are affected by SARS-CoV-2 in the COVID-19 pandemic. MATERIAL AND
methodA systematic review of the literature was carried out based on the international database PubMed focused on miR nature, origin, structure and function in cancer genome and more recently on the influence of SARS-CoV-2 on affected cells. The following keywords were used: microRNA, SARS-CoV-2, COVID-19, infection, cancer, virus. A pool of 52 important articles were selected for the present review at the basis of exploring the SARS-CoV-2 efficacy in miRs.
resultsA broad set of miRs, including miR-122, miR-16-2-3p, miR-3605-3p, miR-15b-5p, miR-486-3p, miR-486-5p, miR-447b, miR-3672, miR-325, miR-447b and miR-222, has been identified to be deregulated by SARS-CoV-2 infection.
conclusionsmiRs represent significant micro-epigenetic markers frequently deregulated in SARS-CoV-2 mediated infection (COVID-19). Interactions between miRs and SARS-CoV-2 RNA genome are under investigation. miR overexpression/expression loss in SARS-CoV-2 affected epithelia is correlated with specific genetic and by epigenetic signatures in the corresponding patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.